NEKTAR THERAPEUTICS Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nektar Therapeutics quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2010 to Q2 2024.
  • Nektar Therapeutics Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$52.4M, a 2.43% decline year-over-year.
  • Nektar Therapeutics Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$177M, a 42.3% increase year-over-year.
  • Nektar Therapeutics annual Net Income (Loss) Attributable to Parent for 2023 was -$276M, a 25% increase from 2022.
  • Nektar Therapeutics annual Net Income (Loss) Attributable to Parent for 2022 was -$368M, a 29.7% increase from 2021.
  • Nektar Therapeutics annual Net Income (Loss) Attributable to Parent for 2021 was -$524M, a 17.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$177M -$52.4M -$1.24M -2.43% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$176M -$36.8M +$100M +73.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$276M -$42.1M +$17.6M +29.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$294M -$45.8M +$13.2M +22.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$307M -$51.1M +$108M +67.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$415M -$137M -$46.6M -51.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$368M -$59.7M +$86M +59% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$454M -$59M +$70.7M +54.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$525M -$159M -$33.5M -26.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$491M -$90.4M +$32.6M +26.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$524M -$146M -$28.4M -24.3% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-01
Q3 2021 -$495M -$130M -$21.1M -19.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 -$474M -$126M -$45.5M -56.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 -$429M -$123M +$15.7M +11.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$444M -$117M -$5.04M -4.49% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$439M -$109M -$10M -10.1% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-01
Q2 2020 -$429M -$80M +$30.3M +27.5% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-01
Q1 2020 -$460M -$139M -$19M -15.9% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-01
Q4 2019 -$441M -$112M -$14M -14.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-26
Q3 2019 -$427M -$98.6M -$2.44M -2.54% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-26
Q2 2019 -$424M -$110M -$1.08B -111% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-26
Q1 2019 $657M -$120M -$23.8M -24.9% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-26
Q4 2018 $681M -$98.2M -$64.4M -190% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 $746M -$96.1M -$157M -258% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-28
Q2 2018 $903M $971M +$1.03B Apr 1, 2018 Jun 30, 2018 10-K 2020-02-28
Q1 2018 -$129M -$95.8M -$31.9M -50% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-28
Q4 2017 -$96.7M -$33.8M +$8.37M +19.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 -$105M $60.9M +$104M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 -$209M -$59.9M -$11.3M -23.2% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 -$198M -$63.9M -$44.4M -228% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 -$154M -$42.2M +$11.9M +22.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$165M -$43.2M -$35M -427% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 -$130M -$48.6M +$4.05M +7.7% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 -$134M -$19.5M -$53.3M -158% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 -$81.2M -$54.1M -$8.45M -18.5% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$72.7M -$8.2M -$78.8M -112% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 $6.09M -$52.7M -$20M -61.3% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 $26.1M $33.8M +$80M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$53.9M -$45.7M +$1.98M +4.15% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-01
Q3 2014 -$55.9M $70.6M +$87.1M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-01
Q2 2014 -$143M -$32.6M +$10.1M +23.7% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-01
Q1 2014 -$153M -$46.2M +$8.86M +16.1% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-01
Q4 2013 -$162M -$47.7M +$5.27M +9.95% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-26
Q3 2013 -$167M -$16.5M +$27M +62% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-26
Q2 2013 -$194M -$42.7M -$8.46M -24.7% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-26
Q1 2013 -$186M -$55.1M -$14M -34% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-26
Q4 2012 -$172M -$52.9M -$15.4M -41.2% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-27
Q3 2012 -$156M -$43.5M -$19.5M -80.9% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-27
Q2 2012 -$137M -$34.3M +$2.1M +5.76% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-27
Q1 2012 -$139M -$41.1M -$5.06M -14.1% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-27
Q4 2011 -$134M -$37.5M -$14.9M -66.1% Oct 1, 2011 Dec 31, 2011 10-K 2013-03-01
Q3 2011 -$119M -$24.1M -$15.4M -176% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-01
Q2 2011 -$104M -$36.4M -$35.9M -6937% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-01
Q1 2011 -$67.8M -$36M -$29.9M -488% Jan 1, 2011 Mar 31, 2011 10-K 2013-03-01
Q4 2010 -$37.9M -$22.6M Oct 1, 2010 Dec 31, 2010 10-K 2012-02-29
Q3 2010 -$8.71M Jul 1, 2010 Sep 30, 2010 10-K 2012-02-29
Q2 2010 -$517K Apr 1, 2010 Jun 30, 2010 10-K 2012-02-29
Q1 2010 -$6.13M Jan 1, 2010 Mar 31, 2010 10-K 2012-02-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.